Expanding Distribution Channels for the Orthopedic Implant アレクサネイル
First written in FY2018. 7 of 25 entries say "Advanced", first in FY2019-Q3. Latest entry: 2026-09-30.
The whole theme swung hardest in 2026: 1 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Mitigated".
- 2026-09-30MitigatedEarnings
「売上高は54百万円（前年同四半期比0.4％増）、セグメント損失は20百万円（前年同四半期は63百万円のセグメント損失）となりました。」
医療機器製造・販売業は増収となり、セグメント損失が前年同期から縮小した。 - FY2026Full-Year Revenue Decline and Narrower LossAnnual report
「The medical device manufacturing and sales business manufactures and sells orthopedic implants developed by the Group and develops and sells medical equipment using ultrasound. Revenue was ¥210 million, down 4.4% year on year, and the segment posted a loss of ¥185 million, compared with a segment loss of ¥220 million in the previous year.」
The medical device manufacturing and sales business reported a full-year decline in revenue, while the segment loss narrowed from ¥220 million in the previous year to ¥185 million. - FY2026-H1Interim-period revenue decline and widening lossAnnual report
「The medical device manufacturing and sales business primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥104 million, down 8.2% year on year, and the segment posted a loss of ¥111 million, compared with a segment loss of ¥82 million in the previous year.」
The medical device manufacturing and sales business, centered on orthopedic implants, reported an 8.2% year-on-year decline in revenue, while the segment loss widened from ¥82 million to ¥111 million. - FY2025-H1Interim-period revenue decline and a shift into the redAnnual report
「The medical device manufacturing and sales business primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥113 million, down 22.8% year on year, and the segment posted a loss of ¥82 million, compared with segment profit of ¥6 million in the previous year.」
The medical device manufacturing and sales business, centered on orthopedic implants, reported a 22.8% year-on-year decline in revenue and changed from profit of ¥6 million in the previous year to a segment loss of ¥82 million. - FY2024Full-year revenue decline and a shift into the redAnnual report
「The medical device manufacturing and sales business primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥267 million, down 6.6% year on year, and the segment posted a loss of ¥1 million, compared with segment profit of ¥12 million in the previous year.」
The medical device manufacturing and sales business, centered on orthopedic implants, reported a full-year decline in revenue and changed from segment profit in the previous year to a segment loss of ¥1 million. - FY2024-Q3Widening declines in revenue and profitsAnnual report
「The medical device manufacturing and sales business primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥209 million, down 1.0% year on year, and segment profit was ¥2 million, down 79.7%.」
The medical device manufacturing and sales business, centered on orthopedic implants, reported a 1.0% year-on-year decline in revenue and a 79.7% decline in profit, changing from increases in both revenue and profit in the previous quarter to declines in both. - FY2024-Q2AdvancedAnnual report
「The medical device manufacturing and sales business primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥146 million, up 4.6% year on year, and segment profit was ¥6 million, up 116.4%.」
The medical device manufacturing and sales business, centered on orthopedic implants, reported a 4.6% year-on-year increase in revenue and a 116.4% increase in segment profit, continuing to post increases in both revenue and profit. - FY2024-Q1AdvancedAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥73 million, up 3.0% year on year, while segment profit was ¥7 million, up 47.8%.」
The medical device manufacturing and sales business, centered on orthopedic implants, changed from a year-on-year decline in revenue and profit to increases in both revenue and profit in the first quarter. - FY2023Lower revenue and profit continuedAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥286 million, down 0.4% year on year, while segment profit was ¥12 million, down 39.9%.」
The medical device manufacturing and sales business, centered on orthopedic implants, posted a full-year revenue decline, while segment profit fell 39.9% year on year. - FY2023-Q3Changed to a decline in both revenue and profitAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥211 million, down 1.1% year on year, while segment profit was ¥10 million, down 12.2%.」
In the medical device manufacturing and sales business, centered on orthopedic implants, revenue decreased 1.1% year on year and segment profit decreased 12.2%, changing from revenue growth and a profit decline in the prior quarter to declines in both revenue and profit. - FY2023-Q2Revenue growth and decline in segment profitAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥140 million, up 2.7% year on year, while segment profit was ¥3 million, down 21.6%.」
In the medical device manufacturing and sales business, centered on orthopedic implants, revenue increased 2.7% while segment profit decreased 21.6% year on year. - FY2023-Q1RestatedAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥71 million, down 1.3% year on year, while segment profit was ¥5 million, down 3.1%.」
In the medical device manufacturing and sales business, centered on orthopedic implants, both revenue and segment profit were below the prior-year levels, and the year-on-year decline in profit continued. - FY2022-Q3Year-on-year profit declines continuedAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥214 million, while segment profit was ¥12 million, down 80.9% year on year.」
In the medical device manufacturing and sales business, centered on orthopedic implants, segment profit fell 80.9% year on year, continuing the year-on-year decline in profit. - FY2022-Q2Segment profit declined sharplyAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥136 million, while segment profit was ¥3 million, down 90.6% year on year.」
In the medical device manufacturing and sales business, centered on orthopedic implants, revenue was ¥136 million and segment profit was ¥3 million, with segment profit falling 90.6% year on year. - FY2022-Q1Segment profit declined year on yearAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥72 million, while segment profit was ¥5 million, down 80.4% year on year.」
In the medical device manufacturing and sales business, centered on orthopedic implants, revenue was ¥72 million and segment profit was ¥5 million, with profit down 80.4% year on year. - FY2021AdvancedAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥359 million, up 10.3% year on year, while segment profit was ¥72 million, up 24.5%.」
Full-year revenue and segment profit in the medical device manufacturing and sales business, centered on orthopedic implants, exceeded the prior-year levels. - FY2021-Q3AdvancedAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥283 million, up 18.7% year on year, while segment profit was ¥63 million, up 25.7%.」
In the medical device manufacturing and sales business, centered on Group-developed orthopedic implants, revenue and segment profit exceeded the prior-year levels. - FY2021-Q1AdvancedAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥109 million, up 39.2% year on year, while segment profit was ¥28 million, up 70.5%.」
In the medical device manufacturing and sales business, centered on orthopedic implants, revenue increased 39.2% year on year and segment profit increased 70.5%. - FY2020Full-year revenue and profit declineAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥326 million, down 12.9% year on year, while segment profit was ¥57 million, down 21.5%.」
Full-year revenue and segment profit in the medical device manufacturing and sales business, centered on orthopedic implants, were below the prior-year levels. - FY2020-Q3Revenue and profit declines continued year on yearAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥238 million, down 16.6% year on year, while segment profit was ¥50 million, down 3.4%.」
In the medical device manufacturing and sales business, centered on orthopedic implants, both revenue and segment profit remained below the prior-year levels. - FY2020-Q2Performance fell below the prior-year levelAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥159 million, down 18.5% year on year, while segment profit was ¥35 million, down 18.4% year on year.」
Revenue and segment profit in the medical device manufacturing and sales business, centered on orthopedic implants, were below the prior-year levels. - FY2020-Q1AdvancedAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥78 million, up 6.8% year on year, while segment profit was ¥16 million, up 83.4%.」
In the medical device manufacturing and sales business, centered on orthopedic implants, revenue increased 6.8% year on year and segment profit increased 83.4%. - FY2019Performance fell below the prior-year levelAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥374 million, down 5.3% year on year, while segment profit was ¥73 million, down 14.2%.」
Revenue and segment profit in the medical device manufacturing and sales business, including orthopedic implants, were below the prior-year levels. - FY2019-Q3AdvancedAnnual report
「In the medical device manufacturing and sales business, the Company primarily manufactures and sells orthopedic implants developed by the Group. Revenue was ¥285 million, up 3.1% year on year, while segment profit was ¥52 million, down 21.4% year on year.」
For the medical device manufacturing and sales business, including the Group-developed orthopedic implant, cumulative nine-month revenue increased 3.1% year on year, while segment profit decreased 21.4%. - FY2018First statedAnnual report
「In the orthopedic implant manufacturing and sales business, distribution channels for Alexa Nail, a product developed by a Group company, have expanded steadily, and the product has grown to become an important part of the Group’s business portfolio.」
Results showed expanded distribution channels and the growing business significance of the orthopedic implant developed by a group company.